Nonalcoholic Fatty Liver Disease

References

1. • Wong V.W.S.
   • Chan W.K.
   • Chitturi S.
   • et al.
   Asia–Pacific Working Party on Non-alcoholic Fatty Liver Disease guidelines 2017—part 1: definition, risk factors and assessment.
   J Gastroenterol Hepatol. 2018; 33: 70-85
   View in Article

   • Google Scholar
2. • Kuchay M.S.
   • Martinez-Montoro J.I.
   • Choudhary N.S.
   • et al.
   Non-Alcoholic Fatty Liver Disease in Lean and Non-Obese Individuals: Current and Future Challenges.
   Biomedicines. 2021; 9: 1346
   View in Article

   • Google Scholar
3. • Le M.H.
   • Yeo Y.H.
   • Li X.
   • et al.
   2019 Global NAFLD Prevalence: A Systematic Review and Meta-analysis.
   Clin Gastroenterol Hepatol. 2021; 20 (e28): 2809-2817
   View in Article

   • Google Scholar
4. • Singh S.
   • Allen A.M.
   • Wang Z.
   • et al.
   Fibrosis progression in nonalcoholic fatty liver vs nonalcoholic steatohepatitis: a systematic review and meta-analysis of paired-biopsy studies.
   Clin Gastroenterol Hepatol. 2015; 13 (e1-9; [quiz: e39-40]): 643-654
   View in Article

   • Google Scholar
5. • Dulai P.S.
   • Singh S.
   • Patel J.
   • et al.
   Increased risk of mortality by fibrosis stage in nonalcoholic fatty liver disease: Systematic review and meta-analysis.
   Hepatology. 2017; 65: 1557-1565
   View in Article

   • Google Scholar
6. • Huang D.Q.
   • El-Serag H.B.
   • Loomba R.
   Global epidemiology of NAFLD-related HCC: trends, predictions, risk factors and prevention.
   Nat Rev Gastroenterol Hepatol. 2021; 18: 223-238
   View in Article

   • Google Scholar
7. • Wong R.J.
   • Aguilar M.
   • Cheung R.
   • et al.
   Nonalcoholic steatohepatitis is the second leading etiology of liver disease among adults awaiting liver transplantation in the United States.
   Gastroenterology. 2015; 148: 547-555
   View in Article

   • Google Scholar
8. • Wong R.J.
   • Cheung R.
   • Ahmed A.
   Nonalcoholic steatohepatitis is the most rapidly growing indication for liver transplantation in patients with hepatocellular carcinoma in the U.S.
   Hepatology. 2014; 59: 2188-2195
   View in Article

   • Google Scholar
9. • National Cholesterol Education Program
   Expert Panel on Detection E, Treatment of High Blood Cholesterol in A. Third Report of the National Cholesterol Education Program (NCEP) Expert Panel on Detection, Evaluation, and Treatment of High Blood Cholesterol in Adults (Adult Treatment Panel III) final report.
   Circulation. 2002; 106: 3143-3421
   View in Article

   • Google Scholar
10. • Alberti K.G.
    • Zimmet P.
    • Shaw J.
    • et al.
    The metabolic syndrome--a new worldwide definition.
    Lancet. 2005; 366: 1059-1062
    View in Article

    • Google Scholar
11. • Sarafidis P.A.
    • Nilsson P.M.
    The metabolic syndrome: a glance at its history.
    J Hypertens. 2006; 24: 621-626
    View in Article

    • Google Scholar
12. • Alberti K.G.
    • Zimmet P.Z.
    Definition, diagnosis and classification of diabetes mellitus and its complications. Part 1: diagnosis and classification of diabetes mellitus provisional report of a WHO consultation.
    Diabet Med. 1998; 15: 539-553
    View in Article

    • Google Scholar
13. • Balkau B.
    • Charles M.A.
    Comment on the provisional report from the WHO consultation. European Group for the Study of Insulin Resistance (EGIR).
    Diabet Med. 1999; 16: 442-443
    View in Article

    • Google Scholar
14. • Chan W.K.
    • Wong V.W.
    Meaning of non-overlapping patients between the MAFLD and NAFLD definitions.
    Liver Int. 2022; 42: 271-273
    View in Article

    • Google Scholar
15. • Eslam M.
    • Newsome P.N.
    • Sarin S.K.
    • et al.
    A new definition for metabolic dysfunction-associated fatty liver disease: An international expert consensus statement.
    J Hepatol. 2020; 73: 202-209
    View in Article

    • Google Scholar
16. • Wong V.W.
    • Hui A.Y.
    • Tsang S.W.
    • et al.
    Prevalence of undiagnosed diabetes and postchallenge hyperglycaemia in Chinese patients with non-alcoholic fatty liver disease.
    Aliment Pharmacol Ther. 2006; 24: 1215-1222
    View in Article

    • Google Scholar
17. • Younossi Z.M.
    • Golabi P.
    • de Avila L.
    • et al.
    The global epidemiology of NAFLD and NASH in patients with type 2 diabetes: A systematic review and meta-analysis.
    J Hepatol. 2019; 71: 793-801
    View in Article

    • Google Scholar
18. • Mantovani A.
    • Petracca G.
    • Beatrice G.
    • et al.
    Non-alcoholic fatty liver disease and risk of incident diabetes mellitus: an updated meta-analysis of 501 022 adult individuals.
    Gut. 2021; 70: 962-969
    View in Article

    • Google Scholar
19. • Kwok R.
    • Choi K.C.
    • Wong G.L.
    • et al.
    Screening diabetic patients for non-alcoholic fatty liver disease with controlled attenuation parameter and liver stiffness measurements: a prospective cohort study.
    Gut. 2016; 65: 1359-1368
    View in Article

    • Google Scholar
20. • Lee H.W.
    • Wong G.L.
    • Kwok R.
    • et al.
    Serial Transient Elastography Examinations to Monitor Patients With Type 2 Diabetes: A Prospective Cohort Study.
    Hepatology. 2020; 72: 1230-1241
    View in Article

    • Google Scholar
21. • Calzadilla-Bertot L.
    • Vilar-Gomez E.
    • Wong V.W.
    • et al.
    ABIDE: An Accurate Predictive Model of Liver Decompensation in Patients With Nonalcoholic Fatty Liver-Related Cirrhosis.
    Hepatology. 2021; 73: 2238-2250
    View in Article

    • Google Scholar
22. • Zhang X.
    • Wong G.L.
    • Yip T.C.
    • et al.
    Risk of liver-related events by age and diabetes duration in patients with diabetes and nonalcoholic fatty liver disease.
    Hepatology. 2022; 76: 1409-1422
    View in Article

    • Google Scholar
23. • Targher G.
    • Corey K.E.
    • Byrne C.D.
    • et al.
    The complex link between NAFLD and type 2 diabetes mellitus - mechanisms and treatments.
    Nat Rev Gastroenterol Hepatol. 2021; 18: 599-612
    View in Article

    • Google Scholar
24. • Younossi Z.M.
    • Koenig A.B.
    • Abdelatif D.
    • et al.
    Global epidemiology of nonalcoholic fatty liver disease-Meta-analytic assessment of prevalence, incidence, and outcomes.
    Hepatology. 2016; 64: 73-84
    View in Article

    • Google Scholar
25. • Polyzos S.A.
    • Kountouras J.
    • Mantzoros C.S.
    Obesity and nonalcoholic fatty liver disease: From pathophysiology to therapeutics.
    Metabolism. 2019; 92: 82-97
    View in Article

    • Google Scholar
26. • Li L.
    • Liu D.W.
    • Yan H.Y.
    • et al.
    Obesity is an independent risk factor for non-alcoholic fatty liver disease: evidence from a meta-analysis of 21 cohort studies.
    Obes Rev. 2016; 17: 510-519
    View in Article

    • Google Scholar
27. • Smith G.I.
    • Mittendorfer B.
    • Klein S.
    Metabolically healthy obesity: facts and fantasies.
    J Clin Invest. 2019; 129: 3978-3989
    View in Article

    • Google Scholar
28. • Cho I.Y.
    • Chang Y.
    • Sung E.
    • et al.
    Weight Change and the Development of Nonalcoholic Fatty Liver Disease in Metabolically Healthy Overweight Individuals.
    Clin Gastroenterol Hepatol. 2022; 20: e583-e599
    View in Article

    • Google Scholar
29. • Lonardo A.
    • Mantovani A.
    • Lugari S.
    • et al.
    Epidemiology and pathophysiology of the association between NAFLD and metabolically healthy or metabolically unhealthy obesity.
    Ann Hepatol. 2020; 19: 359-366
    View in Article

    • Google Scholar
30. • Sookoian S.
    • Pirola C.J.
    Systematic review with meta-analysis: the significance of histological disease severity in lean patients with nonalcoholic fatty liver disease.
    Aliment Pharmacol Ther. 2018; 47: 16-25
    View in Article

    • Google Scholar
31. • Fassio E.
    • Alvarez E.
    • Dominguez N.
    • et al.
    Natural history of nonalcoholic steatohepatitis: a longitudinal study of repeat liver biopsies.
    Hepatology. 2004; 40: 820-826
    View in Article

    • Google Scholar
32. • Jarvis H.
    • Craig D.
    • Barker R.
    • et al.
    Metabolic risk factors and incident advanced liver disease in non-alcoholic fatty liver disease (NAFLD): A systematic review and meta-analysis of population-based observational studies.
    Plos Med. 2020; 17: e1003100
    View in Article

    • Google Scholar
33. • Polyzos S.A.
    • Kountouras J.
    • Mantzoros C.S.
    Adipokines in nonalcoholic fatty liver disease.
    Metabolism. 2016; 65: 1062-1079
    View in Article

    • Google Scholar
34. • Zhao Y.C.
    • Zhao G.J.
    • Chen Z.
    • et al.
    Nonalcoholic Fatty Liver Disease: An Emerging Driver of Hypertension.
    Hypertension. 2020; 75: 275-284
    View in Article

    • Google Scholar
35. • Oikonomou D.
    • Georgiopoulos G.
    • Katsi V.
    • et al.
    Non-alcoholic fatty liver disease and hypertension: coprevalent or correlated?.
    Eur J Gastroenterol Hepatol. 2018; 30: 979-985
    View in Article

    • Google Scholar
36. • Wu S.
    • Wu F.
    • Ding Y.
    • et al.
    Association of non-alcoholic fatty liver disease with major adverse cardiovascular events: A systematic review and meta-analysis.
    Sci Rep. 2016; 6: 33386
    View in Article

    • Google Scholar
37. • Stranges S.
    • Trevisan M.
    • Dorn J.M.
    • et al.
    Body fat distribution, liver enzymes, and risk of hypertension: evidence from the Western New York Study.
    Hypertension. 2005; 46: 1186-1193
    View in Article

    • Google Scholar
38. • Bonnet F.
    • Gastaldelli A.
    • Pihan-Le Bars F.
    • et al.
    Gamma-glutamyltransferase, fatty liver index and hepatic insulin resistance are associated with incident hypertension in two longitudinal studies.
    J Hypertens. 2017; 35: 493-500
    View in Article

    • Google Scholar
39. • Lau K.
    • Lorbeer R.
    • Haring R.
    • et al.
    The association between fatty liver disease and blood pressure in a population-based prospective longitudinal study.
    J Hypertens. 2010; 28: 1829-1835
    View in Article

    • Google Scholar
40. • Ryoo J.H.
    • Suh Y.J.
    • Shin H.C.
    • et al.
    Clinical association between non-alcoholic fatty liver disease and the development of hypertension.
    J Gastroenterol Hepatol. 2014; 29: 1926-1931
    View in Article

    • Google Scholar
41. • Zhang T.
    • Zhang C.
    • Zhang Y.
    • et al.
    Metabolic syndrome and its components as predictors of nonalcoholic fatty liver disease in a northern urban Han Chinese population: a prospective cohort study.
    Atherosclerosis. 2015; 240: 144-148
    View in Article

    • Google Scholar
42. • Aneni E.C.
    • Oni E.T.
    • Martin S.S.
    • et al.
    Blood pressure is associated with the presence and severity of nonalcoholic fatty liver disease across the spectrum of cardiometabolic risk.
    J Hypertens. 2015; 33: 1207-1214
    View in Article

    • Google Scholar
43. • Sorrentino P.
    • Terracciano L.
    • D'Angelo S.
    • et al.
    Predicting fibrosis worsening in obese patients with NASH through parenchymal fibronectin, HOMA-IR, and hypertension.
    Am J Gastroenterol. 2010; 105: 336-344
    View in Article

    • Google Scholar
44. • Ma J.
    • Hwang S.J.
    • Pedley A.
    • et al.
    Bi-directional analysis between fatty liver and cardiovascular disease risk factors.
    J Hepatol. 2017; 66: 390-397
    View in Article

    • Google Scholar
45. • Carnagarin R.
    • Matthews V.
    • Zaldivia M.T.K.
    • et al.
    The bidirectional interaction between the sympathetic nervous system and immune mechanisms in the pathogenesis of hypertension.
    Br J Pharmacol. 2019; 176: 1839-1852
    View in Article

    • Google Scholar
46. • Satou R.
    • Penrose H.
    • Navar L.G.
    Inflammation as a Regulator of the Renin-Angiotensin System and Blood Pressure.
    Curr Hypertens Rep. 2018; 20: 100
    View in Article

    • Google Scholar
47. • Lee H.J.
    • Lee C.H.
    • Kim S.
    • et al.
    Association between vascular inflammation and non-alcoholic fatty liver disease: Analysis by (18)F-fluorodeoxyglucose positron emission tomography.
    Metabolism. 2017; 67: 72-79
    View in Article

    • Google Scholar
48. • Younossi Z.M.
    • Ratziu V.
    • Loomba R.
    • et al.
    Obeticholic acid for the treatment of non-alcoholic steatohepatitis: interim analysis from a multicentre, randomised, placebo-controlled phase 3 trial.
    Lancet. 2019; 394: 2184-2196
    View in Article

    • Google Scholar
49. • Amor A.J.
    • Perea V.
    Dyslipidemia in nonalcoholic fatty liver disease.
    Curr Opin Endocrinol Diabetes Obes. 2019; 26: 103-108
    View in Article

    • Google Scholar
50. • Chalasani N.
    • Younossi Z.
    • Lavine J.E.
    • et al.
    The diagnosis and management of nonalcoholic fatty liver disease: Practice guidance from the American Association for the Study of Liver Diseases.
    Hepatology. 2018; 67: 328-357
    View in Article

    • Google Scholar
51. • Powell E.E.
    • Wong V.W.
    • Rinella M.
    Non-alcoholic fatty liver disease.
    Lancet. 2021; 397: 2212-2224
    View in Article

    • Google Scholar
52. • Ipsen D.H.
    • Lykkesfeldt J.
    • Tveden-Nyborg P.
    Molecular mechanisms of hepatic lipid accumulation in non-alcoholic fatty liver disease.
    Cell Mol Life Sci. 2018; 75: 3313-3327
    View in Article

    • Google Scholar
53. • Zewinger S.
    • Reiser J.
    • Jankowski V.
    • et al.
    Apolipoprotein C3 induces inflammation and organ damage by alternative inflammasome activation.
    Nat Immunol. 2020; 21: 30-41
    View in Article

    • Google Scholar
54. • Kanwal F.
    • Kramer J.R.
    • Li L.
    • et al.
    Effect of Metabolic Traits on the Risk of Cirrhosis and Hepatocellular Cancer in Nonalcoholic Fatty Liver Disease.
    Hepatology. 2020; 71: 808-819
    View in Article

    • Google Scholar
55. • Ng C.H.
    • Wong Z.Y.
    • Chew N.W.S.
    • et al.
    Hypertension is prevalent in non-alcoholic fatty liver disease and increases all-cause and cardiovascular mortality.
    Front Cardiovasc Med. 2022; 9: 942753
    View in Article

    • Google Scholar
56. • Pitisuttithum P.
    • Chan W.K.
    • Goh G.B.
    • et al.
    Gamma-glutamyl transferase and cardiovascular risk in nonalcoholic fatty liver disease: The Gut and Obesity Asia initiative.
    World J Gastroenterol. 2020; 26: 2416-2426
    View in Article

    • Google Scholar
57. • Aminian A.
    • Al-Kurd A.
    • Wilson R.
    • et al.
    Association of Bariatric Surgery With Major Adverse Liver and Cardiovascular Outcomes in Patients With Biopsy-Proven Nonalcoholic Steatohepatitis.
    JAMA. 2021; 326: 2031-2042
    View in Article

    • Google Scholar
58. • Zhou Y.Y.
    • Zhou X.D.
    • Wu S.J.
    • et al.
    Synergistic increase in cardiovascular risk in diabetes mellitus with nonalcoholic fatty liver disease: a meta-analysis.
    Eur J Gastroenterol Hepatol. 2018; 30: 631-636
    View in Article

    • Google Scholar
59. • Mantovani A.
    • Petracca G.
    • Beatrice G.
    • et al.
    Non-alcoholic fatty liver disease and increased risk of incident extrahepatic cancers: a meta-analysis of observational cohort studies.
    Gut. 2022; 71: 778-788
    View in Article

    • Google Scholar
60. • Chen Z.F.
    • Dong X.L.
    • Huang Q.K.
    • et al.
    The combined effect of non-alcoholic fatty liver disease and metabolic syndrome on colorectal carcinoma mortality: a retrospective in Chinese females.
    World J Surg Oncol. 2018; 16: 163
    View in Article

    • Google Scholar
61. • Zhang X.
    • Wong G.L.
    • Yip T.C.
    • et al.
    Angiotensin-converting enzyme inhibitors prevent liver-related events in nonalcoholic fatty liver disease.
    Hepatology. 2022; 76: 469-482
    View in Article

    • Google Scholar
62. • Golabi P.
    • Otgonsuren M.
    • de Avila L.
    • et al.
    Components of metabolic syndrome increase the risk of mortality in nonalcoholic fatty liver disease (NAFLD).
    Medicine (Baltimore). 2018; 97: e0214
    View in Article

    • Google Scholar
63. • Kim D.
    • Konyn P.
    • Sandhu K.K.
    • et al.
    Metabolic dysfunction-associated fatty liver disease is associated with increased all-cause mortality in the United States.
    J Hepatol. 2021; 75: 1284-1291
    View in Article

    • Google Scholar
64. • Kanwal F.
    • Shubrook J.H.
    • Adams L.A.
    • et al.
    Clinical Care Pathway for the Risk Stratification and Management of Patients With Nonalcoholic Fatty Liver Disease.
    Gastroenterology. 2021; 161: 1657-1669
    View in Article

    • Google Scholar
65. • Vilar-Gomez E.
    • Martinez-Perez Y.
    • Calzadilla-Bertot L.
    • et al.
    Weight Loss Through Lifestyle Modification Significantly Reduces Features of Nonalcoholic Steatohepatitis.
    Gastroenterology. 2015; 149 (e5; quiz e14-5): 367-378
    View in Article

    • Google Scholar
66. • Wong V.W.
    • Chan R.S.
    • Wong G.L.
    • et al.
    Community-based lifestyle modification programme for non-alcoholic fatty liver disease: a randomized controlled trial.
    J Hepatol. 2013; 59: 536-542
    View in Article

    • Google Scholar
67. • Wong V.W.
    • Wong G.L.
    • Chan R.S.
    • et al.
    Beneficial effects of lifestyle intervention in non-obese patients with non-alcoholic fatty liver disease.
    J Hepatol. 2018; 69: 1349-1356
    View in Article

    • Google Scholar
68. • Newsome P.N.
    • Buchholtz K.
    • Cusi K.
    • et al.
    A Placebo-Controlled Trial of Subcutaneous Semaglutide in Nonalcoholic Steatohepatitis.
    N Engl J Med. 2021; 384: 1113-1124
    View in Article

    • Google Scholar
69. • Loomba R.
    • Abdelmalek M.F.
    • Armstrong M.
    • et al.
    Semaglutide 2.4 mg once weekly improved liver and metabolic parameters, and was well tolerated, in patients with non-alcoholic steatohepatitis-related cirrhosis: a randomised, placebo-controlled phase 2 trial.
    J Hepatol. 2022; 77: S10
    View in Article

    • Google Scholar
70. • Hsiang J.C.
    • Wong V.W.
    SGLT2 Inhibitors in Liver Patients.
    Clin Gastroenterol Hepatol. 2020; 18: 2168-2172 e2
    View in Article

    • Google Scholar
71. • Lange N.F.
    • Radu P.
    • Dufour J.F.
    Prevention of NAFLD-associated HCC: Role of lifestyle and chemoprevention.
    J Hepatol. 2021; 75: 1217-1227
    View in Article

    • Google Scholar
72. European Association for the Study of the Liver (EASL), European Association for the Study of Diabetes (EASD), European Association for the Study of Obesity (EASO). EASL-EASD-EASO Clinical Practice Guidelines for the management of non-alcoholic fatty liver disease.
    J Hepatol. 2016; 64: 1388-1402
    View in Article

    • Google Scholar
73. • Eslam M.
    • Sarin S.K.
    • Wong V.W.
    • et al.
    The Asian Pacific Association for the Study of the Liver clinical practice guidelines for the diagnosis and management of metabolic associated fatty liver disease.
    Hepatol Int. 2020; 14: 889-919
    View in Article

    • Google Scholar